SCHEMBL14724666

SCHEMBL14724666

CNc1ncc2cc(C)ccc2n1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CYP1A2 P05177 2/20 0.46
▸ NCK1 P16333 1/20 0.43
▸ BACE1 P56817 1/20 0.43
▸ ALDH1A1 P00352 1/20 0.43
▸ EGFR P00533 2/20 0.43
▸ LCK P06239 5/20 0.42
▸ BRAF P15056 2/20 0.42
▸ IKBKB O14920 3/20 0.41
▸ RPS6KA3 P51812 1/20 0.40
▸ KDR P35968 3/20 0.39
▸ MAPK14 Q16539 3/20 0.39
▸ TEK Q02763 1/20 0.39
▸ PDE3B Q13370 1/20 0.39
▸ PDE3A Q14432 1/20 0.39
▸ JAK3 P52333 1/20 0.39
▸ CCNK O75909 1/20 0.39
▸ CCNA2 P20248 1/20 0.39
▸ CDK2 P24941 1/20 0.39
▸ CDK7 P50613 1/20 0.39
▸ CCNH P51946 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24150522 0.85 CYP1A2 (0.47) CYP1A2ALDH1A1EGFRIKBKBRPS6KA3
SCHEMBL14724690 0.80 LCK (0.39) EGFRLCKBRAFKDRMAPK14
SCHEMBL1585490 0.80 EGFR (0.44) BACE1EGFRLCKBRAFKDR
Hydrochloric Acid SCHEMBL5497021 0.79 EGFR (0.43) BACE1EGFRLCKBRAFKDR
SCHEMBL15450886 0.78 PIK3CA (0.54) NCK1BACE1ALDH1A1BRAFCCNK
SCHEMBL11741494 0.78 NCK1 (0.41) CYP1A2NCK1BACE1ALDH1A1RPS6KA3
SCHEMBL14724701 0.78 CDK1 (0.52) CYP1A2LCKBRAFRPS6KA3KDR
SCHEMBL14457345 0.78 MAPK14 (0.43) BRAFRPS6KA3MAPK14
SCHEMBL25449364 0.77 LCK (0.41) EGFRLCKBRAFKDRMAPK14
SCHEMBL25097413 0.77 BRAF (0.43) EGFRLCKBRAF

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2023025912-A1 USE OF GCN2 INHIBITORS IN TREATING CANCER Alesta Therapeutics BV (NL) 2023-03-02 — — WO disclosed
EP-1836174-B1 ARYL NITROGEN-CONTAINING BICYCLIC COMPOUNDS AND THEIR USE AS KINASE INHIBITORS AMGEN INC (US) 2013-02-27 — — EP disclosed
Send feedback